Literature DB >> 16166565

Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants.

Itamar Grosskopf1, Nadine Baroukh, Sung-Joon Lee, Yehuda Kamari, Dror Harats, Edward M Rubin, Len A Pennacchio, Allen D Cooper.   

Abstract

OBJECTIVE: ApoAV, a newly discovered apoprotein, affects plasma triglyceride level. To determine how this occurs, we studied triglyceride-rich lipoprotein (TRL) metabolism in mice deficient in apoAV. METHODS AND
RESULTS: No significant difference in triglyceride production rate was found between apoa5(-/-) mice and controls. The presence or absence of apoAV affected TRL catabolism. After the injection of 14C-palmitate and 3H-cholesterol labeled chylomicrons and (125)I-labeled chylomicron remnants, the disappearance of 14C, 3H, and (125)I was significantly slower in apoa5(-/-) mice relative to controls. This was because of diminished lipolysis of TRL and the reduced rate of uptake of their remnants in apoa5(-/-) mice. Observed elevated cholesterol level was caused by increased high-density lipoprotein (HDL) cholesterol in apoa5(-/-) mice. VLDL from apoa5(-/-) mice were poor substrate for lipoprotein lipase, and did not bind to the low-density lipoprotein (LDL) receptor as well as normal very-low-density lipoprotein (VLDL). LDL receptor levels were slightly elevated in apoa5(-/-) mice consistent with lower remnant uptake rates. These alterations may be the result of the lower apoE-to-apoC ratio found in VLDL isolated from apoa5(-/-) mice.
CONCLUSIONS: These results support the hypothesis that the absence of apoAV slows lipolysis of TRL and the removal of their remnants by regulating their apoproteins content after secretion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166565     DOI: 10.1161/01.ATV.0000186189.26141.12

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  39 in total

1.  Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.

Authors:  G M Dallinga-Thie; A van Tol; H Hattori; L C van Vark-van der Zee; H Jansen; E J G Sijbrands
Journal:  Diabetologia       Date:  2006-04-28       Impact factor: 10.122

2.  An APOA5 3' UTR variant associated with plasma triglycerides triggers APOA5 downregulation by creating a functional miR-485-5p binding site.

Authors:  Cyrielle Caussy; Sybil Charrière; Christophe Marçais; Mathilde Di Filippo; Agnès Sassolas; Mireille Delay; Vanessa Euthine; Audrey Jalabert; Etienne Lefai; Sophie Rome; Philippe Moulin
Journal:  Am J Hum Genet       Date:  2014-01-02       Impact factor: 11.025

Review 3.  Genetic determinants of plasma triglycerides.

Authors:  Christopher T Johansen; Sekar Kathiresan; Robert A Hegele
Journal:  J Lipid Res       Date:  2010-11-01       Impact factor: 5.922

4.  Nutrigenomics: a case for the common soil between cardiovascular disease and cancer.

Authors:  Licia Iacoviello; Iolanda Santimone; Maria Carmela Latella; Giovanni de Gaetano; Maria Benedetta Donati
Journal:  Genes Nutr       Date:  2008-04       Impact factor: 5.523

5.  Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men.

Authors:  Yae Jung Hyun; Yangsoo Jang; Jey Sook Chae; Ji Young Kim; Jean Kyung Paik; So Yeon Kim; Ju Young Yang; Jose M Ordovas; Young Guk Ko; Jong Ho Lee
Journal:  Atherosclerosis       Date:  2008-12-31       Impact factor: 5.162

6.  The ins (cell) and outs (plasma) of apolipoprotein A-V.

Authors:  Trudy M Forte; Xiao Shu; Robert O Ryan
Journal:  J Lipid Res       Date:  2008-12-02       Impact factor: 5.922

Review 7.  Biochemistry and pathophysiology of intravascular and intracellular lipolysis.

Authors:  Stephen G Young; Rudolf Zechner
Journal:  Genes Dev       Date:  2013-03-01       Impact factor: 11.361

8.  Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.

Authors:  Jon C Gonzales; Philip L S M Gordts; Erin M Foley; Jeffrey D Esko
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

9.  Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha.

Authors:  Xian-sheng Huang; Shui-ping Zhao; Lin Bai; Min Hu; Wang Zhao; Qian Zhang
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

10.  Cloning and characterization of a novel apolipoprotein gene, apolipoprotein AV, in tree shrews.

Authors:  Guoping Li; Huairong Luo; Guotao Sun; Guisheng Wu; Gang Wu; Yan Wang; Yong Man; Shu Wang; Jian Li; Baosheng Chen
Journal:  Mol Biol Rep       Date:  2013-05-17       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.